-

Veradigm RxTruePrice Helps Drive Higher Medication Adherence

Allscripts business unit addresses need for better patient medication adherence through pricing transparency

CHICAGO--(BUSINESS WIRE)--Allscripts Healthcare Solutions (NASDAQ: MDRX) and its payer and life science business unit, Veradigm™, announced its findings on the impact of Veradigm’s RxTruePrice™, a solution designed to address patient challenges resulting in them foregoing, discontinuing or substituting their prescribed medication due to cost and a lack of prescription drug price transparency.

Recent studies have revealed alarming statistics surrounding low medication adherence. For example, 33% of patients have purposely missed filling a prescription due to its prohibitive cost.1 And nearly 6% of patients have skipped taking their medications three times or more.1

Patient outcomes may improve if it were easier to ensure patients stay on their prescribed medication regimen by knowing the cost before they leave their doctor’s office. Higher out-of-pocket cost of prescription medications have been shown to correlate with increased prescribed prescription abandonment. With patients incurring a higher share of their healthcare costs, Veradigm’s RxTruePrice can help the 42% of Americans, who have reported they are struggling to pay for their necessary medication, gain a clearer view into pricing. 1

A recent Veradigm fielded study found that six out of ten RxTruePrice users have observed an overall improvement in patient prescription medication adherence since launching the solution.2 Users also felt that the availability of pricing data within their regular workflow held the potential to help them improve medication adherence as compared to alternate solutions, such as sponsored patient support programs and patient reminders.2

Used by tens of thousands of providers for tens of millions of price transparency transactions, Veradigm RxTruePrice provides users access to discounted health plan or pharmacy-benefit pricing, cash pricing, therapeutic alternatives and competitive prices at local and mail-order pharmacies. Further, all information is specific to each individual patient and is accessible in the provider’s e-prescribing workflow.

“Everyone knows healthcare costs are rising and people’s incomes can’t always keep up,” says RxTruePrice client Dr. Darla Kincaid of MD Pediatric Associates, in Coppell, TX. “Having that patient’s drug pricing information right there in the EHR, it makes for a phenomenal tool. It has helped us improve medication adherence as a practice, but just as importantly, it helps us better engage our patients. By demonstrating we share their concerns on cost of care, it makes us a team, and that is the goal.”

“Veradigm RxTruePrice is positioned to help bridge the gaps created by pharmaceutical companies’ pricing structures and positive patient outcomes,” said Veradigm CEO Tom Langan, “medication adherence is not a new problem, but now, it is a problem with a solution.”

Learn more about the impact of Veradigm RxTruePrice solution here.

1. Hamm, N. Managed Healthcare Executive. How High Drug Prices Affect Patients. May 2019. Available at https://www.managedhealthcareexecutive.com/drug-price/how-high-drug-prices-affect-patients

2. Results of Veradigm ePrescribe user survey conducted September 2019. Data on File.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Contacts

For more information contact:
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

Allscripts Healthcare Solutions Logo
Allscripts Healthcare Solutions Logo

Allscripts Healthcare Solutions

NASDAQ:MDRX

Release Versions
Hashtags

Contacts

For more information contact:
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

More News From Allscripts Healthcare Solutions

Veradigm Provides Business and Strategy Update

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said...

Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution

CHICAGO--(BUSINESS WIRE)--Veradigm (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm’s FollowMyHealth pat...

Veradigm to Release Business Update February 17th and Host Investor Call February 18th

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company’s update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the c...
Back to Newsroom